Schlosser S F, Almeida O F, Patchev V K, Yassouridis A, Elands J
Department of Neuroendocrinology, Max Planck Institute of Psychiatry, Munich, Germany.
Endocrinology. 1994 Nov;135(5):2058-63. doi: 10.1210/endo.135.5.7956927.
Previous work showed the existence of receptors for arginine vasopressin (AVP) in the anterior pituitary; these receptors were classified as belonging to a distinct AVP receptor subtype, referred to as AVP-V1b receptors, and are thought to mediate the well documented ACTH-releasing activity of AVP. In the present work, high affinity receptors for another neurohypophyseal hormone, oxytocin (OT), were also shown to be present within the rat anterior pituitary; to this end, [125I]d(CH2)5[Tyr(Me)2Thr4Tyr-NH2(9)]OVT was used as a ligand in receptor binding studies. Experiments on dispersed rat anterior pituitary cells in a superfusion system confirmed earlier reports that OT acts as an additional secretagogue of ACTH, with significant effects first seen at concentrations as low as 1 nM. Further studies addressed the question of whether stimulation of ACTH release is mediated by OT receptors or whether receptors for AVP (V1b receptors) might serve this role. For this, highly selective agonist and antagonist ligands of the OT receptor and nonselective agonist and antagonist ligands of the V1b receptor were employed. Neither the OT receptor agonist Thr4Gly7OT nor the OT receptor antagonist des-Gly(NH2)9d(CH2)5-[Tyr(Me)2 Thr4]OVT displayed any influence on basal ACTH release, and des-Gly(NH2)9d(CH2)5-[Tyr(Me)2Thr4]OVT did not interfere with OT-induced ACTH release; these results indicated that OT promotes ACTH release through a receptor(s) other than the OT receptor itself. Evidence for the involvement of AVP V1b receptors was provided by the observation that the AVP receptor antagonist dP[Tyr(Me2)]AVP completely abolished OT-elicited increases in ACTH release. Thus, AVP V1b receptors mediate the actions of two structurally related peptides on ACTH secretion; the role of OT receptors in adenohypophyseal function remains to be determined.
先前的研究表明,垂体前叶存在精氨酸加压素(AVP)受体;这些受体被归类为一种独特的AVP受体亚型,称为AVP-V1b受体,被认为介导了AVP已被充分证明的促肾上腺皮质激素(ACTH)释放活性。在本研究中,还发现大鼠垂体前叶存在另一种神经垂体激素——催产素(OT)的高亲和力受体;为此,在受体结合研究中使用了[125I]d(CH2)5[Tyr(Me)2Thr4Tyr-NH2(9)]OVT作为配体。在超灌注系统中对分散的大鼠垂体前叶细胞进行的实验证实了早期的报道,即OT作为ACTH的另一种促分泌素,在低至1 nM的浓度下就可产生显著作用。进一步的研究探讨了ACTH释放的刺激是由OT受体介导,还是AVP(V1b受体)受体可能发挥这一作用的问题。为此,使用了OT受体的高度选择性激动剂和拮抗剂配体以及V1b受体的非选择性激动剂和拮抗剂配体。OT受体激动剂Thr4Gly7OT和OT受体拮抗剂des-Gly(NH2)9d(CH2)5-[Tyr(Me)2 Thr4]OVT对基础ACTH释放均无任何影响,且des-Gly(NH2)9d(CH2)5-[Tyr(Me)2Thr4]OVT不干扰OT诱导的ACTH释放;这些结果表明,OT通过OT受体本身以外的受体促进ACTH释放。AVP V1b受体参与其中的证据来自以下观察结果:AVP受体拮抗剂dP[Tyr(Me2)]AVP完全消除了OT引起的ACTH释放增加。因此,AVP V1b受体介导了两种结构相关肽对ACTH分泌的作用;OT受体在腺垂体功能中的作用仍有待确定。